Eric D. Malek
Directeur/Bestuurslid bij Cascade Prodrug, Inc.
Profiel
Eric D.
Malek is currently a Director at Cascade Prodrug, Inc. He was previously a Vice President-Corporate Development at Allos Therapeutics, Inc. and at Threshold Pharmaceuticals, Inc. from 2010 to 2016.
Mr. Malek has an undergraduate degree from the University of Arizona and an MBA from the University of Michigan.
Actieve functies van Eric D. Malek
Bedrijven | Functie | Begin |
---|---|---|
Cascade Prodrug, Inc.
Cascade Prodrug, Inc. Pharmaceuticals: MajorHealth Technology Cascade Prodrug, Inc. engages is the research and development of targeted prodrug therapies. It provides technology for the treatment of hyper-proliferative diseases. The company was founded by August J. Sick and Allan Cochrane and is headquartered in Eugene, OR. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Eric D. Malek
Bedrijven | Functie | Einde |
---|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Corporate Officer/Principal | - |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Corporate Officer/Principal | - |
Opleiding van Eric D. Malek
University of Michigan | Masters Business Admin |
University of Arizona | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Cascade Prodrug, Inc.
Cascade Prodrug, Inc. Pharmaceuticals: MajorHealth Technology Cascade Prodrug, Inc. engages is the research and development of targeted prodrug therapies. It provides technology for the treatment of hyper-proliferative diseases. The company was founded by August J. Sick and Allan Cochrane and is headquartered in Eugene, OR. | Health Technology |